On Invalid Date, Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 2023 earnings per share (EPS) of $0.52, up 174.29% year over year. Total Protagonist Therapeutics earnings for the quarter were $27.34 million. In the same quarter last year, Protagonist Therapeutics's earnings per share (EPS) was -$0.70.
As of Q1 2024, Protagonist Therapeutics's earnings has grown year over year. Protagonist Therapeutics's earnings in the past year totalled -$78.96 million.
What is PTGX's earnings date?
Protagonist Therapeutics's earnings date is Invalid Date. Add PTGX to your watchlist to be reminded of PTGX's next earnings announcement.
What was PTGX's revenue last quarter?
On Invalid Date, Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 2023 revenue of $60.00 million up Infinity% year over year. In the same quarter last year, Protagonist Therapeutics's revenue was $0.00.
What was PTGX's revenue growth in the past year?
As of Q1 2024, Protagonist Therapeutics's revenue has grown 125.73% year over year. This is 43.57 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Protagonist Therapeutics's revenue in the past year totalled $60.00 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.